

IND OPEN MEETING

CHELSEA HOTEL, TORONTO, ON
ROOM: MOUNTBATTEN SALON
DATE: FRIDAY MAY 3 9 AM-12 PM

CHAIR : DR. PHILIPPE BEDARD
IND PROGRAM DIRECTOR : DR. LESLEY SEYMOUR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To summarize aspects of recent developments in the understanding of immunotherapy, novel therapeutic agents as these relate to specific malignancies and their therapeutic targets.
- To describe and discuss results of recent Investigational New Drug studies conducted by the CCTG.
- To explain aspects of new clinical trial methodologies in the field of early cancer drug development.

9:00 am	Welcome	Dr Philippe Bedard
9:05 am	IND Team Awards announcement	
9:10 am	Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award & Lecture:	Dr Alex Wyatt
9:30 am	IND 222- A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme <ul style="list-style-type: none"> • Final results 	Dr Warren Mason
9:40 am	IND 226- A phase Ib study of durvalumab (MEDI4736) with or without tremelimumab in patients with advanced incurable solid malignancies given with or without standard chemotherapy regimens. <ul style="list-style-type: none"> • Final results 	Dr Desiree Hao / Dr Rosalyn Juergens
10:00 am	Cell Therapy & Plans	Dr John Kuruvilla / Dr Annette Hay
10.30 am	Ovarian Platform Study (IPROC)	Dr Helen MacKay
<u>New Trials</u>		
10:50 am	IND.236- A phase Ib and open label phase II study of CFI-402257 in combination with weekly paclitaxel in patients with advanced/metastatic HER2-negative breast cancer	Dr Philippe Bedard / Dr. Mihaela Mates
11:00 am	IND.237- A phase II study of CFI-400945 in patients with advanced/metastatic breast cancer	Dr David Cescon / Dr. Rossanna Pezo



11:10 am	IND.239- A multicenter phase Ib/II study of polo-kinase 4 inhibitor CFI-400945 + the PD-L1 inhibitor durvalumab in patients with triple negative breast cancer	Dr David Cescon / Dr. Andrew Robinson
11:20 am	IND.238- A phase II study of durvalumab retreatment in patients who discontinued prior checkpoint therapy due to immune related toxicity	Dr Peter Ellis / Dr. Sara Taylor
<u>Current Trial Updates</u>		
11:30 am	IND.228- A phase II study of durvalumab and tremelimumab in patients with advanced rare tumours.	Dr Abha Gupta/ Dr. Torsten Nielsen / Dr. Ming Tsao
11:40 am	IND. 232- A phase II study of durvalumab (MEDI4736) with or without tremelimumab in patients with metastatic castration resistant prostate cancer	Dr Eric Winkvist
11:50 am	IND.235- A phase II open label, randomized non-comparative trial of nivolumab alone or in combination with ipilimumab for the treatment of patients with advanced hypermutated solid tumours detected by a blood based assay.	Dr Patricia Tang
12:00 pm	Close	Dr Rosalyn Juergens